We’re now designing drugs from scratch using AI, skipping years of trial-and-error in the lab. The biotech company #Profluent just introduced #ProGen3, a next-gen #AIModel that creates complex #proteins by learning from billions of existing examples.
ProGen3 is built with a staggering 46 billion parameters, trained on over 3 billion real protein sequences—an unprecedented leap in #generativebiology. The outcome? New antibodies just as effective as those already on the market—but different enough to sidestep patent issues.
Even more groundbreaking are the mini genetic tools: gene-editing proteins that are less than half the size of CRISPR-Cas9. That kind of miniaturization unlocks possibilities for #genetherapies we could barely imagine before.
And Profluent isn’t holding back: they’re releasing 20 AI-generated antibodies under open licenses to treat diseases affecting more than 7 million people—no closed patents, no royalties. A radical shift for the #biotechindustry.
But here’s the real game-changer: the laws of #AIscaling now apply to biology. More data, bigger models, better results. If the trend holds, developing new drugs could move from years of lab work to a rapid #engineeringroutine.
And this is just the beginning of a revolution that’s about to reshape everything.
